Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition by Monroe, D. et al.
Novel mouse hemostasis model for real-time determination of 
bleeding time and hemostatic plug composition
T. M. GETZ*, R. PIATT*, B. G. PETRICH†, D. MONROE*,‡, N. MACKMAN*,‡, and W. 
BERGMEIER*,§
*McAllister Heart Institute, University of North Carolina, Chapel Hill, NC
†Department of Pediatrics, EMORY University, Atlanta, GA
‡Department of Medicine, University of North Carolina, Chapel Hill, NC
§Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA
Summary
Introduction—Hemostasis is a rapid response by the body to stop bleeding at sites of vessel 
injury. Both platelets and fibrin are important for the formation of a hemostatic plug. Mice have 
been used to uncover the molecular mechanisms that regulate the activation of platelets and 
coagulation under physiologic conditions. However, measurements of hemostasis in mice are quite 
variable, and current methods do not quantify platelet adhesion or fibrin formation at the site of 
injury.
Methods—We describe a novel hemostasis model that uses intravital fluorescence microscopy to 
quantify platelet adhesion, fibrin formation and time to hemostatic plug formation in real time. 
Repeated vessel injuries of ~ 50–100 μm in diameter were induced with laser ablation technology 
in the saphenous vein of mice.
Results—Hemostasis in this model was strongly impaired in mice deficient in glycoprotein Ibα 
or talin-1, which are important regulators of platelet adhesiveness. In contrast, the time to 
hemostatic plug formation was only minimally affected in mice deficient in the extrinsic tissue 
factor (TFlow) or the intrinsic factor IX coagulation pathways, even though platelet adhesion was 
significantly reduced. A partial reduction in platelet adhesiveness obtained with clopidogrel led to 
instability within the hemostatic plug, especially when combined with impaired coagulation in 
TFlow mice.
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Conclusions—In summary, we present a novel, highly sensitive method to quantify hemostatic 
plug formation in mice. On the basis of its sensitivity to platelet adhesion defects and its real-time 
imaging capability, we propose this model as an ideal tool with which to study the efficacy and 
safety of antiplatelet agents.
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Introduction
Platelets are critical in the first phase of hemostatic plug formation, as they quickly form 
aggregates on the exposed subendothelium. Although platelet aggregates may be sufficient 
to transiently stop bleeding, the formation of a stable hemostatic plug requires blood 
coagulation, i.e. the generation of thrombin and the conversion of fibrinogen to crosslinked 
fibrin. Once formed, fibrin serves as a glue that reinforces the platelet plug.
Platelet integrins play an essential role in hemostasis, as they mediate platelet adhesion to 
the subendothelium and platelet–platelet cohesion [1], both in arterioles and in venules. The 
major platelet integrin is αIIbβ3, which is a receptor for fibrinogen and von Willebrand factor 
(VWF) deposited at sites of vascular injury. Binding of αIIbβ3 to these ligands depends on its 
ability to change from a low-affinity to a high-affinity state, a process controlled by 
intracellular signaling events [2]. Critical to this affinity modulation is talin-1, an adapter 
protein that connects the integrin to the cytoskeleton. Platelet-specific deletion of talin-1 
leads to markedly impaired hemostasis, spontaneous hemorrhage, and protection from 
thrombosis [3,4]. Glycoprotein (GP)Ib–V–IX, another receptor for VWF, is expressed in a 
high-affinity state on resting platelets. The GPIb–VWF interaction mediates transient 
platelet adhesion (tethering), and is particularly important for thrombus formation under 
conditions of high shear stress [5,6]. Hemostasis is less impaired in mice with defects in the 
expression or function of GPIb–V–IX than in mice lacking αIIbβ3 or talin-1 [7].
At sites of vascular injury, the extrinsic, tissue factor (TF)-dependent pathway triggers 
coagulation, whereas the intrinsic pathway is critical for amplification of the clotting 
response. TF-dependent activation of coagulation is required for hemostasis [8]. Low-level 
expression of human TF (~ 1% relative to mouse TF) rescued the lethality in TF null 
embryos [9]. TF-mediated activation of factor X leads to the generation of a small amount of 
thrombin and the deposition of some fibrin at the margins of wounds [10]. This extrinsic 
pathway fibrin is not sufficient for hemostasis, as shown by the bleeding in 
thrombocytopathies that are associated with thrombin generation defects [11]. Thrombin 
generation through the intrinsic pathway is required for normal hemostasis, and deficiency 
in FXI, FIX or FVIII leads to bleeding [12-14].
Mice are the most widely used animals for studying the molecular mechanisms underlying 
hemostasis [15]. It is important to remember, however, that conclusions drawn from studies 
in mice have to be interpreted with caution, as there are significant differences between the 
hemostatic systems of mice and humans. These differences include the absence of protease-
activated receptor 1 [16] and Fcγ receptor RIIA from mouse platelets [17], the absence of 
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protein C inhibitor in mouse plasma [18], and differences in the TF pathway inhibitor 
isoforms expressed in mouse and human tissue [19]. The mouse model, however, has 
several important advantages, including the availability of genetically modified mice, the 
relatively low costs of mice, and the strong similarities in the vascular system between mice 
and humans. Measuring hemostasis, however, is challenging in these small animals. In the 
tail clip assay, the most commonly used method to study hemostasis in mice [20], the tail tip 
is amputated, and the bleeding time and the amount of blood loss are recorded. Given the 
severity of the lesion and the many reported modifications of the model, however, it is not 
surprising that there is substantial variability in results, both within the same group of study 
mice and between different laboratories. A less severe and more standardized hemostasis 
model is based on repeated puncture injury to the saphenous vein [21]. Bleeding times in 
this model are generally < 100 s, reflecting the smaller injuries than with tail transection. 
Another important advantage of this model is the ability to repeatedly disrupt the hemostatic 
plug, i.e. the ability to obtain multiple bleeding times from the same animal. Just like the tail 
bleeding time assay, however, this model does not quantify platelet adhesion or thrombin-
dependent fibrin formation at the site of injury.
We describe a novel method for the quantitative analysis of platelet adhesion, thrombin/
fibrin formation and bleeding time in mice. In this model, a standardized vascular injury to 
the saphenous vein is induced with laser ablation technology and hemostatic plug formation 
and bleeding are assessed by intravital microscopy.
Materials and methods
Materials
Low molecular weight heparin (enoxaparin sodium) and clopidogrel bisulfate (Plavix) were 
from Sanofi-Aventis (Bridgewater, NJ, USA). Heparin-coated capillaries were from VWR 
(West Chester, PA, USA). Bovine serum albumin (fraction V), prostacyclin (prostaglandin 
I2), and ADP (Sigma-Aldrich, St. Louis, MO, USA). An antibody against GPIX was from 
Emfret Analytics (Wuerzburg, Germany). An antibody against fibrin was a kind gift from R. 
Camire (Children’s Hospital of Philadelphia).
Animals
Talin1f/fPF4-Cre [22], IL4R/GPIb-tg [7], FIX−/− [13], TFlow [9] and wild-type (WT) control 
mice were bred on a C57BL6/J strain background, and housed in the mouse facility of the 
University of North Carolina at Chapel Hill. Genotypes were verified by PCR analysis. All 
experimental procedures were approved by the Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill. Where indicated, mice were treated (by oral 
gavage) with clopidogrel bisulfate (75 mg kg−1 body weight) 24 h and 3 h before the 
experiment, to inhibit P2Y12 signaling in circulating platelets [23].
Laser-induced injury to the saphenous vein
Mice (12–14 weeks of age) were anesthetized by intraperitoneal injection of ketamine/
xylazine (100 and 10 mg kg−1, respectively) (Med-Vet International, Mettawa, IL, USA). 
An Alexa488-labeled antibody against GPIX (2.5 μg per mouse) and an Alexa647-labeled 
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antibody against fibrin (4 μg per mouse) were administered by retro-orbital injection. The 
saphenous vein was exposed as described recently [17], and the vessel was exposed to two 
maximum-strength 532-nm laser pulses (70 μJ; 100 Hz; duration, 7 ns; interval between 
pulses. 10 ms) (Ablate! photoablation system; Intelligent Imaging Innovations, Denver, CO, 
USA), focused through a × 20 water immersion objective lens (Zeiss, Jena, Germany) with a 
numerical aperture of 1 and a working distance of 1.8 mm. Fluorescence signals were 
recorded for 4.5 min before the same site was reinjured as described above. After 5 min of 
recording, another injury was inflicted at the same site, and fluorescence signals were 
recorded for another 5 min. A schematic representation of the main components of the 
microscopy setup and the time-line of the repeated injury model are provided in Fig. S1A, 
B. Similar injuries were performed at up to five distinct locations along the saphenous vein. 
The bleeding time was recorded when occlusion of the lesion lasted for > 15 s. To avoid 
effects from earlier injuries, new injuries were performed upstream of the previous injury. 
No trends in platelet accumulation (Fig. S2) or bleeding times (not shown) were observed 
between different injury locations along the saphenous vein. Throughout the experiment, 
constant perfusion drip was maintained on the exposed saphenous vein with a physiologic 
salt solution containing 32 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2 mM CaCl2, and 18 mM 
NaHCO3 (pH 7.4), which was bubbled with 5% CO2/95% N2 for 15 min prior to the start of 
the experiment. The physiologic salt solution was maintained at 37 °C by perfusion through 
a Sloflo In-line solution heater (SF-28) (Warner Instruments, Hamden, CT, USA). 
Fluorescence signals within the boundaries of the saphenous vein were recorded with a Zeiss 
Axio Examiner Z1 microscope (Intelligent Imaging Innovations) equipped with a multi-
color LED light source (Lumencor) and a × 20/1 numerical aperture water immersion 
objective lens (Zeiss). All data were analyzed with SLIDEBOOK 5.0 (Intelligent Imaging 
Innovations).
Statistics
Statistical analyses were performed with PRISM (GraphPad Software, Inc., La Jolla, CA, USA) 
or SLIDEBOOK 5.0 (Intelligent Imaging Innovations). A P-value of ≤ 0.05 was considered to be 
significant. All data are presented as mean ± standard error of the mean.
Results
Novel method to visualize hemostatic plug formation
Fluorescently labeled antibodies against GPIX, a subunit of the VWF receptor complex, and 
against fibrin were infused into anesthetized mice, and the saphenous vein was exposed as 
described recently [21]. A top-down injury to the vessel wall was induced by laser ablation, 
resulting in vascular denudation (lesion area, ~ 1800 μm2; diameter, ~ 48 μm) and blood loss 
from the site of injury (Fig. 1; Video S1). Platelet (Fig. 1A,B) and fibrin (Fig. 1A,C) 
accumulation occurred rapidly at the site of injury, and hemostasis was achieved ~ 10 s after 
laser injury (Fig. 1D). Platelet accumulation (anti-GPIX fluorescence) reached its maximum 
~ 1 min after laser-induced damage, before diminishing over time (Fig. 1B). Fibrin 
accumulation was slightly delayed relative to platelet accumulation, and was predominantly 
observed in a ring around the platelet plug (Fig. 1C). To determine whether a repeated injury 
would lead to increased fibrin generation and more robust fibrin binding within the platelet 
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plug, we reinjured the initial site, and again monitored platelet plug and fibrin formation for 
an additional 5 min. Upon the second injury (lesion area, ~ 2600 μm2; diameter, ~ 57 μm), 
significant increases in the accumulation of platelets and the accumulation of fibrin were 
observed. However, fibrin was still mostly seen in a ring around the platelet plug. A third 
injury (lesion area, ~ 3300 μm2; diameter, ~ 65 μm) was performed at the initial site, which 
again led to increased platelet and fibrin accumulation (Fig. 1A). Repeated laser damage to 
the same site led to a small but significant prolongation of the bleeding time (Fig. 1D).
Platelets play a critical role in small injury hemostasis
To assess the contribution of platelets to hemostasis after laser injury to the saphenous vein, 
we first examined platelet plug and fibrin formation in mice lacking talin-1 in 
megakaryocytes/platelets only (talin1f/fPF4-Cre). As shown previously, platelets lacking 
talin-1 fail to aggregate in response to various agonists, including thrombin, thromboxane 
A2, and collagen [22]. As expected, platelet adhesion was markedly impaired and 
hemostasis was not achieved at sites of laser injury in talin1f/fPF4-Cre mice (Fig. 2A,B,D; 
Video S2). The continued blood loss into the surrounding tissue led to a dramatic increase in 
fibrin formation (Fig. 2A,C). Hemostasis was also impaired in mice lacking the extracellular 
domain of GPIbα (IL4R/GPIb-tg mice) (Fig. 2D) [7]. However, platelet accumulation at the 
site of injury was greater than in talin1f/fPF4-Cre mice, leading to a narrowing of the 
opening in the vessel wall (Fig. 2A,B; Video S3). Consistent with the fact that IL4R/GPIb-tg 
platelets aggregate normally in response to agonist stimulation [6], large thrombi were 
observed in the extravascular space. As in talin1f/fPF4-Cre mice, fibrin accumulation was 
markedly increased at sites of injury in IL4R/GPIb-tg mice (Fig. 2A,C). Together, these 
studies show that: (i) platelet adhesion/aggregation plays a critical role in small injury 
hemostasis as tested in this novel model; and (ii) shear stress in the saphenous vein must be 
high enough for platelet adhesion to be (partially) dependent on GPIb–V–IX.
Coagulation augments small injury hemostasis
TF is a critical component of the extrinsic coagulation pathway and the initiation of 
coagulation at sites of vascular injury [8]. To evaluate the contribution of TF to hemostasis 
after laser injury, we examined mice deficient in mouse TF but expressing low levels (~ 1% 
of normal) of human TF [9] in our model. Surprisingly, hemostasis at sites of laser injury in 
these TFlow mice was comparable to that in WT mice (Fig. 3A–D; Video S4), although a 
small but significant prolongation of the bleeding time was observed after the second and 
third injuries (Fig. 3D). Consistent with the predicted role of TF in thrombin generation at 
sites of vascular injury, the accumulation of both platelets and fibrin was significantly 
reduced in these mice (Fig. 3B,C). As in the TFlow mice, the bleeding time in mice deficient 
in the intrinsic coagulation pathway (FIX−/−) was only minimally prolonged (Fig. 3D). 
Whereas platelet accumulation was significantly lower at sites of laser injury in FIX−/− mice 
(Fig. 3B), fibrin formation was increased as compared with controls (Fig. 3C; Video S5). 
These findings are consistent with a model in which the intrinsic pathway is important for 
sustained thrombin generation and full platelet activation at sites of injury. The increased 
fibrin levels may reflect plasma leakage through the porous plug, leading to TF-dependent 
thrombin generation in the extravascular space.
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Analysis of combined defects in platelet function and coagulation
Intrigued by the findings in the TFlow and FIX−/− mice, we investigated whether a proper 
coagulation response would be critical for small injury hemostasis in mice with partially 
defective platelet function. To address this question, we studied hemostatic plug formation 
in WT and TFlow mice pretreated with the P2Y12 inhibitor clopidogrel bisulfate. P2Y12 
inhibition significantly reduced platelet accumulation (Fig. 4A,B) but not fibrin 
accumulation (Fig. 4C) in WT mice. The bleeding time in WT/clopidogrel mice was 
minimally prolonged (Figs. 4D) and thrombus stability was decreased, especially following 
the first insult to the vessel (Video S6; numbers in the bar graph in Fig. 4D indicate the 
percentage of injuries that reopened after hemostatic plug formation). Interestingly, 
clopidogrel treatment led to a significantly increased bleeding time resulting from 
hemostatic plug instability in TFlow mice as compared with WT controls (Fig. 4G; Video 
S7), demonstrating the importance of both thrombin generation and feedback signaling by 
ADP in this model of small injury hemostasis. Consistently, platelet accumulation at the site 
of injury tended to be lower in clopidogrel-treated TFlow mice than in untreated TFlow mice 
(Fig. 4E), whereas fibrin formation was slightly increased at sites of injury in clopidogrel-
treated TFlow mice (Fig. 4F).
Discussion
We describe a new model for the quantitative analysis of platelet accumulation, thrombin/
fibrin generation and bleeding at a site of vascular injury. This novel method has several 
defining characteristics, including the use of intravital fluorescence microscopy to monitor 
the hemostatic process, the novel use of laser ablation technology to generate vascular 
lesions with a defined diameter, the ability to repeatedly disrupt the hemostatic process at 
the same site of injury, and the possibility of performing multiple injuries along the exposed 
saphenous vein. Thus, whereas classic murine hemostasis models, such as the tail clip assay, 
provide only one data point per mouse, our model can yield up to 15 bleeding time 
measurements per animal, and at the same time provide real-time analysis of platelet 
accumulation and fibrin formation at the site of injury.
The tail clip assay is the most widely used method to measure hemostasis in mice. However, 
there are many variables, including where and how the injury is inflicted, the method of 
blood collection, and vascular spasms associated with the transection of the various tail 
vessels, that make standardization of this assay a big challenge [20,24]. In contrast, laser 
ablation generates a small lesion area, does not transect the vessel, and does not cause 
visible vascular spasms. As a result, we obtained very reproducible bleeding time 
measurements for most genotypes tested in this study. Mice lacking the extracellular domain 
of GPIbα constituted an exception, as they were characterized by large variability in the 
bleeding times. As shown by intravital microscopy, this variability in hemostatic function is 
a reflection of the delayed adhesion of IL4R/GPIb-tg platelets and the resulting gradual 
occlusion of the vascular lesion. However, large thrombi accumulated in the surrounding 
tissue, confirming previous findings that the hemostatic defect in these mice is not the result 
of impaired aggregation of these platelets [6].
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In addition to classic bleeding time models, investigators have used various intravital 
microscopy-based methods to monitor thrombus formation at sites of vascular injury 
[25,26]. The FeCl3-induced and the laser-induced cremaster models are both considered to 
be thrombosis models, not hemostasis models. Neither injury leads to significant blood loss 
at the site of injury, unlike in our model, where we observe bleeding from the injured 
saphenous vein. Recent work by Motto et al. further suggests that FeCl3 injury does not lead 
to significant exposure of subendothelial matrix, but that it causes the formation of 
complexes between red blood cells and ferric ions along the exposed vasculature. These 
complexes ultimately recruit platelets from the flowing blood [27]. Unlike laser injury, 
FeCl3 leads to the formation of occlusive thrombi, in both small and large vessels. A 
vascular injury model, induced by puncture with a micropipette, has been described by van 
Gestel et al. [28,29]. In this model, 6–8-μm injuries are made in small mesenteric arterioles, 
20–40 μm in diameter. In contrast, we induce larger injuries (~ 50 μm in diameter) in the 
much larger saphenous vein. Consistently, bleeding times in the micropipette model are very 
short (1–2 s), and P2Y12 inhibition had no significant effect on the bleeding time or the rate 
of rebleeding. In contrast, our studies showed a significant prolongation of the bleeding time 
and an increased rate of rebleeding in mice treated with clopidogrel. Both studies 
demonstrate that P2Y12 inhibition reduces the size of the platelet plug after vessel wall 
injury. We acknowledge that our model is dependent on the availability of rather expensive 
laser ablation technology. As compared with the micropipette puncture model, however, it 
has the advantage that the same optics are used to injure the endothelium and to monitor 
platelet and fibrin accumulation (Fig. S1). This ability to injure while we perform real-time 
imaging allows us to ‘surgically’ remove an existing plug by repeated laser exposure.
Our studies in mice with severe defects in platelet adhesion or coagulation suggest that the 
laser injury model mimics hemostatic defects induced by small-vessel lesions in humans. 
Specifically, we observed a critical role for platelets, but not coagulation, in the formation of 
a hemostatic plug after laser injury to the saphenous vein. Similarly, impaired platelet 
function frequently leads to prolonged bleeding times at sites of small-vessel lesions in 
humans (skin cuts and mucocutaneous lesions) [30]. In contrast, patients with coagulation 
disorders frequently show delayed occurrence of large hematomas, which are thought to 
reflect the critical role of fibrin in the stabilization of larger thrombi. Delayed bleeding was 
also described for mice with impaired clotting function after challenge in the tail clip assay, 
i.e. a more severe injury model [31]. When the bleeding time is used as a read-out, 
hemostasis after laser injury is largely independent of coagulation. The ability to visualize 
hemostatic plug formation in real time, however, provided additional information on the 
hemostatic process in these mice. Platelet accumulation was significantly reduced in both 
TFlow and FIX−/− mice, even though the bleeding time was not prolonged. In contrast, fibrin 
accumulation was markedly increased in lesions of talin1f/fPF4-Cre, IL4R/GPIb-tg and 
FIX−/− mice, whereas it was decreased in TFlow mice. These findings suggest that prolonged 
plasma exposure to TF leads to increased thrombin and fibrin generation in the surrounding 
tissue. As the bleeding time in FIX−/− mice was only minimally increased, we propose that 
hemostatic plugs in these animals are more porous than those in control mice, a conclusion 
that would be consistent with the increased plasma leakage into the joints of hemophilic 
patients. Further studies will be required to test this hypothesis.
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The laser injury model also allows for repeated injuries to the same site, leading to a 
progressive increase in the lesion area and thus increased platelet/fibrin signals and 
prolonged bleeding times. This graded injury response provides additional sensitivity in 
situations where a single injury did not reveal marked defects in hemostatic plug formation. 
For example, a single injury to the saphenous vein of TFlow mice did not lead to an increase 
in the bleeding time as compared with control mice. However, a small but significant 
increase in the bleeding time was observed after the second and third injuries, consistent 
with the minor hemostatic defect observed in these mice after tail transection [32]. A further 
increase in the sensitivity of our assay to clotting defects was observed in mice treated with 
the P2Y12 inhibitor clopidogrel bisulfate. Whereas clopidogrel administration had only a 
small effect on clot stability and the bleeding time after laser injury in WT mice, it markedly 
impaired hemostasis in TFlow mice. This finding is in good agreement with the markedly 
increased bleeding observed in hemophilic patients who are given platelet inhibitors [33]. 
Thus, partial inhibition of platelet function provides a powerful tool with which to sensitize 
the laser injury hemostasis model for coagulation defects.
In summary, we describe here a novel method to monitor and quantify the hemostatic 
process in mice. Small injuries are generated along the exposed saphenous vein with the use 
of a laser ablation system, and platelet adhesion and fibrin accumulation are monitored by 
intravital microscopy. Studies in mutant mice defective in platelet adhesion or coagulation 
further suggest this assay as a model for hemostasis after small-vessel lesions in humans, i.e. 
a situation where hemostasis is largely dependent on the ability of platelets to form a 
hemostatic plug. On the basis of this sensitivity to platelet adhesion defects and its real-time 
imaging capability, we propose this model as an ideal tool with which to study the efficacy 
and safety of antiplatelet agents.
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Quantitative analysis of platelet accumulation, fibrin generation and bleeding time after laser 
injury to the saphenous vein of wild-type mice. Mice were injected with Alexa647-labeled 
antibodies against fibrin and Alexa488-labeled antibodies against glycoprotein (GP)IX to 
monitor fibrin generation and platelet accumulation, respectively. Repeated vascular injury 
was induced by laser ablation. (A) Representative images at the indicated times after the 
start of the recording. (B, C) Accumulation of platelets (B) and fibrin (C). The sum 
fluorescence intensity (SFI) ± standard error of the mean is shown. Total number of injuries 
at distinct locations: n = 15 (obtained in four experimental mice). (D) Bleeding time. *P < 
0.05.
GETZ et al. Page 11














Contribution of platelets to hemostasis after laser injury. Vascular lesions were induced in 
wild-type (WT) (black line/symbols), talin1f/fPF4-Cre (red) and IL4R/GPIb-tg (blue) mice. 
(A) Representative images. (B, C) Accumulation of platelets (B) and fibrin (C). Sum 
fluorescence intensity (SFI) ± standard error of the mean is shown. Talin1f/fPF4-Cre: n = 9 
(four mice). IL4R/GPIb-tg: n = 10 (four mice). (D) Bleeding time. **P < 0.001, ***P < 
0.0001.
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Contribution of the extrinsic and intrinsic coagulation pathways to hemostasis after laser 
injury. Vascular lesions were induced in wild-type (WT) (black line/symbols), TFlow (red) 
and FIX−/− (blue) mice. (A) Representative images. (B, C) Accumulation of platelets (B) 
and fibrin (C). Sum fluorescence intensity (SFI) ± standard error of the mean is shown. 
TFlow: n = 9 (three mice). FIX−/−: n = 13 (three mice). (D) Bleeding time. *P < 0.05, **P < 
0.001, ***P < 0.0001. GP, glycoprotein; TF, tissue factor.
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Effect of clopidogrel on hemostasis in wild-type (WT) and TFlow mice. WT and TFlow mice 
were treated with the P2Y12 inhibitor clopidogrel bisulfate prior to laser injury. (A) 
Representative images. (B–D) Platelet accumulation (B), fibrin accumulation (C) and 
bleeding time (D) in WT (black line/bars) and WT/clopidogrel (green) mice. (E–G) Platelet 
accumulation (E), fibrin accumulation (F) and bleeding time (G) in TFlow (red line/bars) or 
TFlow/clopidogrel (green) mice. Sum fluorescence intensity (SFI) ± standard error of the 
mean is shown. *P < 0.05, **P < 0.001, ***P < 0.0001. WT/clopidogrel: n = 10 (three 
mice). TFlow/clopidogrel: n = 10 (three mice). Numbers in bars indicate the incidence of 
repeated bleeding during the 5-min observation period following laser injury. The bleeding 
time was recorded when occlusion of the lesion lasted for > 15 s. GP, glycoprotein; TF, 
tissue factor.
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